Get the Stockscreener App
2.99
0.66%
-0.02
After Hours:
2.99
Boundless Bio Inc stock is traded at $2.99, with a volume of 299.00K.
It is down -0.66% in the last 24 hours and down -1.97% over the past month.
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
See More
Previous Close:
$3.01
Open:
$3.07
24h Volume:
299.00K
Relative Volume:
4.85
Market Cap:
$67.57M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-16.48%
1M Performance:
-1.97%
6M Performance:
-69.08%
1Y Performance:
+0.00%
1-Day Range:
$2.9558
$3.07
1-Week Range:
$2.885
$3.75
52-Week Range:
$2.82
$12.65
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio Inc
Sector
Industry
Phone
(858) 766-9912
Address
9880 CAMPUS POINT DRIVE, SAN DIEGO
Compare BOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BOLD | 2.99 | 67.57M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Boundless Bio Inc Stock (BOLD) Latest News
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
Science Spotlight: How extrachromosomal DNA drives cancer - BioCentury
Extrachromosomal DNA acts as joker for cancer cells - BioWorld Online
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Stanford Scientists Overturn Mendel’s Law With Shocking Cancer Discovery - SciTechDaily
Enhancing transcription–replication conflict targets ecDNA-positive cancers - Nature.com
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - The Manila Times
Boundless Bio Prices IPO At $16/Shr - RTTNews
Boundless Bio CFO Jami Rubin steps down By Investing.com - Investing.com Australia
Boundless Bio CFO Jami Rubin Steps Down for Personal Reasons - MarketWatch
Boundless Bio CFO Jami Rubin steps down - Investing.com
Boundless Bio Announces Departure of Chief Financial Officer - The Bakersfield Californian
Ceribell begins trading with upsized IPO - BioWorld Online
Down rounds don’t aid post-IPO performance - BioCentury
Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth? - Yahoo Finance
Varun Dhawan's niece Anjini Dhawan's debut film Binny and Family release postponed - India Today
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients - GlobeNewswire
Limitless Labs Secures $3M Pre-Seed Funding Led by 1confirmation - iGaming.org
FDA Grants Breakthrough Status to Achondroplasia Drug By Investing.com - Investing.com Canada
Limitless Labs Secures $3M in Pre-Seed Funding Led by 1confirmation - Blockster
A New Prediction Market Raises $3M in Pre-Seed Round Led by 1confirmation - CoinDesk
'Binny And Family' pushed again; to now release on this date - NewsBytes
The War On Drugs On Beyoncé Collaboration: 'It’s Arguably The Coolest Thing I’ve Ever Done' - Dig!
Antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer - Medical Xpress
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference - ForexTV.com
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewswire Inc.
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Down -31.59% in 4 Weeks, Here's Why You Should You Buy the Dip in Boundless Bio, Inc. (BOLD) - MSN
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024 - Morningstar
Boundless Bio resets stock option prices to retain talent - Investing.com
Boundless Bio Adjusts Stock Options to Incentivize Key Staff - TipRanks
Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out - RTTNews
No sleep for the biotech bear: Restructurings abound in August - BioCentury
Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance - Yahoo Finance
Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now? - Insider Monkey
BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024 - MSN
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results - wallstreet:online
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter - The Bakersfield Californian
10 Best New Penny Stocks To Buy Now - Insider Monkey
A Guide To The Risks Of Investing In Boundless Bio Inc. (BOLD) - Knox Daily
Recent Insider Activity Suggests Potential Gains for Ellington Financial Inc (EFC) - Knox Daily
Deluxe Corp. [DLX] Investment Guide: What You Need to Know - Knox Daily
Integer Holdings Corp [ITGR] Investment Appeal on the Rise - Knox Daily
Informatica Inc [INFA] Insider Schweitzer John Arthur sells 64,501 Shares - Knox Daily
Global stock market crash likely to delay biotech IPOs - Yahoo Finance
Boundless Bio Inc Stock (BOLD) Financials Data
There is no financial data for Boundless Bio Inc (BOLD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):